[EN] AN ADVANTAGEOUS PROCESS FOR PREPARING ANAGLIPTIN AND ITS NOVEL CRYSTALLINE FORM-H [FR] PROCÉDÉ AVANTAGEUX DE PRÉPARATION D'ANAGLIPTINE ET DE SA NOUVELLE FORME CRISTALLINE -H
[EN] PYRROLIDINE COMPOUNDS<br/>[FR] COMPOSES DE PYRROLIDINE
申请人:NAT HEALTH RESEARCH INSTITUTES
公开号:WO2005087235A1
公开(公告)日:2005-09-22
A compound of the following formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Y, Z, m, n, and p are as defined herein. This invention also covers methods for inhibiting dipeptidyl peptidase IV or VIII, or treating Type II diabetes with such a compound.
[EN] A PROCESS FOR PREPARATION OF ANAGLIPTIN HYDROCHLORIDE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'HYDROCHLORURE D'ANAGLIPTINE
申请人:LUPIN LTD
公开号:WO2016012927A1
公开(公告)日:2016-01-28
The present invention relates to process for preparing dipeptidyl peptidase IV inhibitor Anagliptin free base or its hydrochloride salt by using novel methane sulfonic acid salt of (2S)-1-[(1-Amino-2-methylpropan-2-yl) amino] acetyl} pyrrolidine-2-carbonitrile (formula IIa). Anagliptin is used for the treatment of diabetes.
Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
In the course of our program for discovery of novel DPP-IV inhibitors, a series of pyrazolo[1,5-a]pyrimidines were found to be novel DPP-IV inhibitors. We identified N-[2-(2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (4a) and described its pharmacological profiles. (C) 2011 Elsevier Ltd. All rights reserved.